BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9326194)

  • 21. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
    Chessels JM; Swansbury GJ; Reeves B; Bailey CC; Richards SM
    Br J Haematol; 1997 Oct; 99(1):93-100. PubMed ID: 9359508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.
    Mitchell C; Richards S; Harrison CJ; Eden T
    Leukemia; 2010 Feb; 24(2):406-18. PubMed ID: 20010621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).
    Pinkerton CR; Bowman A; Holtzel H; Chessells JM
    Arch Dis Child; 1987 Jan; 62(1):12-8. PubMed ID: 3468886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).
    Hill FG; Richards S; Gibson B; Hann I; Lilleyman J; Kinsey S; Mitchell C; Harrison CJ; Eden OB;
    Br J Haematol; 2004 Jan; 124(1):33-46. PubMed ID: 14675406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
    Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
    J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL trials, 1972-84. Report to the Council by the Working Party on Leukaemia in Childhood.
    Lancet; 1986 Feb; 1(8478):408-11. PubMed ID: 2868339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Rheingold SR; Tasian SK; Whitlock JA; Teachey DT; Borowitz MJ; Liu X; Minard CG; Fox E; Weigel BJ; Blaney SM
    Br J Haematol; 2017 May; 177(3):467-474. PubMed ID: 28295182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study.
    Li CK; Chik KW; Ha SY; Lee AC; Yuen HL; Ling SC; Lee V; Chan GC; Shing MM; Chan LC; Ng MH
    Hong Kong Med J; 2006 Feb; 12(1):33-9. PubMed ID: 16495587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
    Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
    Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
    Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
    de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
    Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
    Lawson SE; Harrison G; Richards S; Oakhill A; Stevens R; Eden OB; Darbyshire PJ
    Br J Haematol; 2000 Mar; 108(3):531-43. PubMed ID: 10759711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI).
    Hargrave DR; Hann II; Richards SM; Hill FG; Lilleyman JS; Kinsey S; Bailey CC; Chessells JM; Mitchell C; Eden OB;
    Br J Haematol; 2001 Feb; 112(2):293-9. PubMed ID: 11167821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.
    Chessells JM; Harrison CJ; Watson SL; Vora AJ; Richards SM;
    Br J Haematol; 2002 May; 117(2):306-14. PubMed ID: 11972512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
    Balduzzi A; Valsecchi MG; Uderzo C; De Lorenzo P; Klingebiel T; Peters C; Stary J; Felice MS; Magyarosy E; Conter V; Reiter A; Messina C; Gadner H; Schrappe M
    Lancet; 2005 Aug 20-26; 366(9486):635-42. PubMed ID: 16112299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematological changes and predictors of bone marrow recovery in patients with neutropenic episodes in acute lymphoblastic leukemia.
    Bhatnagar S; Chandra J; Narayan S
    J Trop Pediatr; 2002 Aug; 48(4):200-3. PubMed ID: 12200979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
    Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
    Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.